{
    "root": "cf0962ad-4f57-4733-a836-844ac7764a01",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phenobarbital",
    "value": "20250508",
    "ingredients": [
        {
            "name": "PHENOBARBITAL",
            "code": "YQE403BP4D"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        }
    ],
    "indications": null,
    "contraindications": "dose phenobarbital must individualized full knowledge particular characteristics . factors consideration patients age , weight , condition .",
    "warningsAndPrecautions": "phenobarbital oral solution 20 mg/5 ml supplied 1 pint ( 473ml ) bottles ndc # 69367-367-16. contains alcohol , 14 % dispense tight , light-resistant container defined usp/nf child-resistant closure .",
    "adverseReactions": "phenobarbital contraindicated patients hypersensitive barbiturates , patients history manifest latent porphyria , patients marked impairment liver function respiratory disease dyspnea obstruction evident .",
    "contraindications_original": "The dose of phenobarbital must be individualized with full knowledge of it particular characteristics. Factors of consideration are the patients age, weight, and condition.",
    "warningsAndPrecautions_original": "Phenobarbital Oral Solution 20 mg/5 mL is supplied in 1 Pint (473mL) bottles NDC# 69367-367-16.\n                  Contains alcohol, 14%\n                  Dispense in a tight, light-resistant container as defined in the USP/NF with a child-resistant closure.",
    "adverseReactions_original": "Phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident."
}